Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Almitrine bismesylate.

J Tweney1, P Howard

  • 1University Department of Medicine, Royal Hallamshire Hospital Sheffield/UK.

Zeitschrift Fur Erkrankungen Der Atmungsorgane
|January 1, 1987
PubMed
Summary
This summary is machine-generated.

Almitrine bismesylate, a respiratory stimulant, effectively increases oxygen levels by stimulating chemoreceptors. However, its long half-life, potential adverse effects, and unclear impact on mortality require further research before defining its clinical use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pilot monitoring strategy for post-partum disease in an Australian dairy herd.

New Zealand veterinary journal·2021
Same author

'Warning: allergic to penicillin': association between penicillin allergy status in 2.3 million NHS general practice electronic health records, antibiotic prescribing and health outcomes.

The Journal of antimicrobial chemotherapy·2019
Same author

A One Health investigation of Salmonella enterica serovar Wangata in north-eastern New South Wales, Australia, 2016-2017.

Epidemiology and infection·2019
Same author

Man in Weightlessness.

Journal of the Royal College of Physicians of London·2019
Same author

A national quality incentive scheme to reduce antibiotic overuse in hospitals: evaluation of perceptions and impact.

The Journal of antimicrobial chemotherapy·2018
Same author

Human resources estimates and funding for antibiotic stewardship teams are urgently needed: authors' response.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2018
Same journal

[Resolutions of the World Conference for Lung Health 20 to 24 May 1990 in Boston, USA].

Zeitschrift fur Erkrankungen der Atmungsorgane·1991
Same journal

[Bronchoalveolar lavage--a diagnostic method in chronic nonspecific bronchopulmonary diseases in childhood? 2. Studies of cellular and humoral parameters in BAL irrigation fluid].

Zeitschrift fur Erkrankungen der Atmungsorgane·1991
Same journal

Pulmonary Lymphogranulomatosis.

Zeitschrift fur Erkrankungen der Atmungsorgane·1991
Same journal

[Work capacity evaluation in nonspecific lung diseases in a polyclinic section for lung diseases and tuberculosis].

Zeitschrift fur Erkrankungen der Atmungsorgane·1991
Same journal

[Ambulatory follow-up of soot dust exposed workers].

Zeitschrift fur Erkrankungen der Atmungsorgane·1991
Same journal

[Reference values for spirometry exemplified by FVC and FEV1 parameters--comparison of normal values of the Pathophysiology of Respiration Section and the European Society for Coal and Steel].

Zeitschrift fur Erkrankungen der Atmungsorgane·1991
See all related articles

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Clinical Therapeutics

Background:

  • Orally active respiratory stimulants have a therapeutic role.
  • Almitrine bismesylate is a respiratory agonist with unique mechanisms of action.

Purpose of the Study:

  • To evaluate the efficacy and safety of almitrine bismesylate as a respiratory stimulant.
  • To explore its mechanisms, pharmacokinetic profile, and potential clinical applications.

Main Methods:

  • Review of existing evidence on almitrine bismesylate's effects on blood gases, pulmonary vasculature, and patient tolerance.
  • Analysis of its pharmacokinetic properties, including plasma elimination half-life.
  • Consideration of potential adverse effects and their relationship to dosage and patient characteristics.

Related Experiment Videos

Main Results:

  • Almitrine bismesylate uniquely increases PaO2 primarily via peripheral chemoreceptor stimulation.
  • Chronic administration results in a long plasma elimination half-life (20-30 days), potentially leading to accumulation.
  • Conflicting evidence exists regarding its long-term effects on pulmonary hemodynamics, and adverse effects on dyspnea and peripheral nerve function are noted in some patients.

Conclusions:

  • Almitrine bismesylate effectively increases PaO2 but its clinical utility is not yet clearly defined.
  • Demonstrating a mortality benefit in respiratory failure or hypoxemia is crucial for establishing its therapeutic value.
  • Further research is needed to clarify its mechanisms, optimize dosing, and identify patient subgroups who benefit most while minimizing adverse effects.